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Abstract
The plasma protein vitronectin is thought to be an important regulator of extravascular plasminogen activation. In
previous studies we have shown that a disulfide stabilized multimeric form of vitronectin is endocytosed and degraded by
fibroblast cells (T.S. Panetti, P.J. McKeown-Longo, J. Biol. Chem. 268 (1993) 11988^11993; P.J. McKeown-Longo, T.S.
Panetti, in: K.T. Preissner, S. Rosenblatt, C. Kost, J. Wegerhoff, D.F. Mosher (Eds.), Biology of Vitronectins and their
Receptors, Elsevier Science Publishers, Amsterdam, 1993, pp. 111^118). The preparation of multimeric vitronectin used in
these earlier studies was in the form of high molecular weight disulfide-bonded aggregates which were stable in sodium
dodecyl sulfate (SDS). To address the question of whether vitronectin needed to be in the form of disulfide stabilized
multimers in order to be endocytosed, a multimeric vitronectin, which was not disulfide stabilized, was prepared from
vitronectin that had been treated with reducing agent and alkylated with iodoacetamide. The resulting protein migrated as a
65/75 kDa protein on SDS gels in the absence of reducing agent, confirming that this form of vitronectin was no longer
stabilized into disulfide-bonded aggregates. However, the protein was still multimeric when analyzed by native gels and could
be converted to SDS stable multimers by cross-linking agents. This result demonstrated that reduced and alkylated
vitronectin aggregates into multimeric forms which are not stable in SDS. Similar to disulfide stabilized multimers, alkylated
multimers of vitronectin bound to sulfated proteoglycans in the extracellular matrix and were endocytosed and degraded.
Degradation of both forms of vitronectin was inhibited with arginine-glycine-aspartic acid peptides, an anti-KvL5 antibody
and heparin. Chloroquine and wortmannin were also able to inhibit degradation of both forms of vitronectin, indicating that
both multimeric forms were following the same endocytic and degradative pathway. These results suggest that the
organization of vitronectin into a multimeric form which will be recognized for endocytosis does not require disulfide bond
stabilization. This study further suggests that recognition of vitronectin for endocytosis is dependent upon its conversion
from a monomeric to a multivalent form (C.E. Wilkins-Port, P.J. McKeown-Longo, Mol. Biol. Cell 8:S:64A (1997). 0167-
4889 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Vitronectin is a 75 kDa plasma protein which is
also found distributed in the extracellular matrix of
various tissues in vivo [3,4]. It is a conformationally
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labile molecule, existing primarily as a monomer in
its native form in the blood; however, a small per-
centage of plasma vitronectin has also been shown to
exist in an alternative conformation that forms ag-
gregates [5]. Homo-multimers of vitronectin have
been found in platelet K granules [6] and are released
from platelets following activation [7]. Association of
native, monomeric vitronectin with thrombinWanti-
thrombin [8,9] or the terminal complement complex
C5b-7 [10,11] results in conformational changes in
the vitronectin molecule that can be detected through
the expression of antibody epitopes which are not
present in the native molecule. Changes in vitronec-
tin’s conformation have also been associated with
altered speci¢city in ligand binding domains. For
example, the ability of vitronectin to interact with
L-endorphin [12], plasminogen activator inhibitor
type-1 (PAI-1) [13], the urokinase receptor [14] and
cells [15], is either initiated or enhanced by confor-
mational changes in the molecule. In addition,
homo-multimerization of vitronectin also results in
the generation of neoepitopes [16,17] demonstrating
that multimer formation is associated with confor-
mational changes in the molecule.
Puri¢cation of vitronectin from serum, under de-
naturing conditions [18], or treatment of plasma vi-
tronectin with chaotropic agents, yields conforma-
tionally altered vitronectin that spontaneously
aggregates to form multimers [19,20]. Sei¡ert et al.
have shown that while multimers puri¢ed from plate-
let K granules and multimers derived from urea
denatured vitronectin do share certain commonal-
ities, it is also apparent that platelet multimers re-
main somewhat distinct from denatured vitronectin
multimers in their level of multimerization and their
expression of certain conformationally sensitive epi-
topes [6]. This may suggest that the generation of
multivalent vitronectin in vitro through the utiliza-
tion of denaturants and the generation of multivalent
vitronectin in vivo through interaction with biologi-
cal stimuli, represent variants in a continuum of vi-
tronectin structural diversity.
Studies have shown that altering the conformation
of the vitronectin molecule also appears to alter the
biological activity of the protein. The interaction of
vitronectin with thrombinWanti-thrombin leads to its
transcytosis into the subendothelial matrix of endo-
thelial cells in culture [21], a mechanism postulated
to be both opsonic for the clearance of thrombinWan-
ti-thrombin complexes [21], and facultative for the
deposition of multivalent vitronectin into extravascu-
lar spaces [21,22]. In addition, multimeric vitronectin
speci¢cally has been shown to bind to the luminal
surface of endothelial cells in culture and translocate
into the subcellular matrix [23], become preferentially
cleared in vivo from the circulation of rabbits [24],
and facilitate the internalization of asbestos ¢bers by
rabbit pleural mesothelial cells [25]. We have previ-
ously shown that multimeric vitronectin binds to the
matrix of cultured ¢broblasts [1,2] and is subse-
quently endocytosed and degraded in lysosomes
[1,26]. Endocytosis is speci¢c for the multimeric
form of vitronectin as native monomeric vitronectin
is not endocytosed, even though both forms bind to
proteoglycans present in the matrix [1,2,27]. We have
also shown that endocytosis of multimeric vitronec-
tin is a regulated event, requiring vitronectin to in-
teract sequentially with sulfated proteoglycans and
the KvL5-integrin [26^28].
Structurally, vitronectin contains a high a⁄nity
binding site for PAI-1 in its N-terminal somatomedin
B domain [29,30]. PAI-1, which inhibits cell surface
bound urokinase-type plasminogen activator [31], is
stabilized in its active conformation by binding to
vitronectin in the extracellular matrix [32^34]. Inter-
estingly, PAI-1 has recently been shown to induce
conformational changes in, and multimerization of
plasma vitronectin [35]. The forces stabilizing these
PAI-1 induced vitronectin multimers appeared to be
di¡erentially regulated in a time dependent manner,
appearing initially as non-covalent interactions and
progressing over time into covalent disul¢de stable
interactions [35,36]. Taken together, these studies
suggest that the structural conversion of vitronectin
from its native to its altered, multivalent form is
functionally signi¢cant.
In the present study, we used two methodologies
to prepare disul¢de stabilized and non-disul¢de sta-
bilized vitronectin multimers, and compared their
metabolism in human skin ¢broblast monolayers.
Urea treated vitronectin that has been puri¢ed by
heparin a⁄nity chromatography is present in the
form of disul¢de stabilized multimers. Multimeric
forms of vitronectin which are not disul¢de stabilized
can be prepared by reduction and alkylation [10]. We
have been able to demonstrate that endocytosis and
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degradation of alkylated vitronectin proceeds in a
manner analogous to that observed for disul¢de
bond stabilized vitronectin. These ¢ndings demon-
strate that the organization of vitronectin into multi-
mers which are recognized for endocytosis by ¢bro-
blasts is not dependent upon the formation of either
intra- or intermolecular disul¢de bonds, but may in-
stead depend upon alternative non-covalent protein-
protein interactions. This study also suggests that it
is the multivalency of vitronectin, rather than
changes in its tertiary structure, which ‘signal’ its
endocytosis and degradation (see Section 4).
2. Materials and methods
2.1. Cell culture
Human foreskin ¢broblasts (A1-F) were a gift
from Dr. Lynn Allen-Ho¡man (University of Wis-
consin, Madison, WI). Cells were maintained at
37‡C, 8% CO2, in DMEM supplemented with 10%
fetal bovine serum (Hyclone, Logan UT), penicillin
(100 U/ml) and streptomycin (100 Wg/ml). Cells were
seeded into T-75 £asks (Corning/Costar) at 5U105
cells/£ask, and grown to con£uence in 5^7 days.
For experiments, ¢broblasts between passages 4
and 13 were seeded in 24-well plates, grown to con-
£uence, and then treated with fresh ascorbate (50 Wg/
ml) daily for 3 days. For experiments in which cells
were treated with sodium chlorate to inhibit proteo-
glycan sulfation, sodium chlorate (at concentrations
indicated in the legend to Fig. 5) was added to
DMEM supplemented with 20% dialyzed fetal bo-
vine serum (Hyclone, Logan, UT), as recommended
by Humphries et al. [37]. Following ascorbate treat-
ment, cell layers were pretreated with chlorate con-
taining medium daily for 3 days prior to the day of
the experiment. Chlorate concentrations were also
maintained during the course of experimental incu-
bation with 125I-vitronectins.
2.2. Materials
Lyophilized arginine-glycine-aspartic acid-serine
(RGDS) (Arg-Gly-Asp-Ser) and arginine-glycine-glu-
tamic acid-serine (RGES) (Arg-Gly-Glu-Ser) pepti-
des (Sigma, St. Louis, MO) were reconstituted and
diluted in DMEM to provide ¢nal working concen-
trations of 0.5, 1.0 and 2.0 mM. Chloroquine, wort-
mannin and heparin were also purchased from Sig-
ma. Chloroquine, which was used to inhibit
lysosomal enzymes, was solubilized in DMEM and
diluted into incubation medium to achieve a ¢nal
concentration of 100 WM. In experiments which uti-
lized chloroquine, cell layers were pretreated with the
drug 15 min prior to the addition of 125I-vitronectin,
and maintained in chloroquine during the course of
the experiment. Wortmannin was solubilized in ster-
ile DMSO to produce a stock concentration of
10 mM, aliquots of which were stored at 320‡C until
use. This was diluted further in DMEM to produce
¢nal concentrations of 0.10^10 WM for use in cell
experiments. In these experiments, an equivalent vol-
ume of DMSO was added to control wells. The ¢nal
concentration of DMSO was less than 1%. Initially,
cell layers were pretreated with wortmannin for
15 min prior to the addition of labeled vitronectin.
Since wortmannin is unstable in aqueous solutions
ranging in pH from 3 to 8 [38], an additional aliquot
was added to cells halfway through the 7 h incuba-
tion period. Heparin (derived from porcine intestinal
mucosa) was solubilized in DMEM to produce a
stock concentration of 10 mg/ml. This was diluted
further in DMEM to achieve ¢nal working concen-
trations of 0.25, 0.5 and 1.0 mg/ml for incubation
with cell layers. For these experiments, 125I-vitronec-
tin or 125I-alkylated vitronectin and heparin were in-
cubated together in DMEM containing 0.2% bovine
serum albumin (BSA), for 1 h prior to their addition
to cell layers.
The monoclonal antibody to the KvL5-integrin,
P1F6, was isolated from mouse ascites (Gibco
BRL, Gaithersburg, MD) using the MAPS II System
(Bio-Rad, Hercules, CA) which speci¢cally optimizes
binding and recovery of mouse IgG1. Brie£y, a 1.0 ml
column of Protein A Sepharose 4 Fast Flow (Phar-
macia, Uppsala, Sweden) was equilibrated with bind-
ing bu¡er (Bio-Rad), pH 9.0. Lyophilized P1F6 as-
cites £uid was reconstituted with the same binding
bu¡er, and applied to the protein A Sepharose col-
umn. Following column washes with binding bu¡er,
the antibody was eluted with elution bu¡er (Bio-
Rad) pH 3.0. Elution fractions were collected into
aliquots of Tris-HCl pH 9.0 to neutralize the pH.
Fractions containing the protein were pooled and
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dialyzed against phosphate bu¡ered saline (PBS).
Aliquots were frozen and stored at 320‡C until
use. For experiments in which P1F6 was used to
block binding to the KvL5-integrin, the stock solution
was diluted to a ¢nal concentration of 20 Wg/ml in
DMEM prior to its addition to cell layers.
2.3. Puri¢cation, reduction/alkylation and iodination
of vitronectin
Conformationally altered vitronectin was puri¢ed
by heparin a⁄nity chromatography, from human
plasma according to the method of Yatohgo et al.
[18]. This puri¢cation method results in a prepara-
tion of vitronectin containing high molecular weight
multimers ranging in size from 500 000 to 950 000
[10,19,20]. A proportion of these multimers are sta-
bilized by intermolecular disul¢de cross-links, the
rest are stabilized, in part, by intramolecular disul¢de
bonds [8,39]. To produce multimers which are not
stabilized by either inter or intra molecular disul¢des,
puri¢ed vitronectin was reduced and alkylated [10].
Brie£y, 2.5^3 mg of puri¢ed vitronectin was diluted
in 100 mM NaPO4 pH 7.4 to achieve a ¢nal protein
concentration of approx. 1.0 mg/ml. Vitronectin was
reduced by adding dithiothreitol (10 mM), followed
by a 3 h incubation at room temperature. Free sulf-
hydryls were alkylated by the addition of iodoaceta-
mide (60 mM) for 1 h at room temperature, in the
dark. The protein solution was dialyzed extensively
against PBS at 4‡C, then aliquoted, £ash frozen and
stored at 380‡C until use. The integrity of the pro-
tein was checked by 10% sodium dodecyl sulfate-pol-
yacrylamide gel electrophoresis (SDS-PAGE). Native
vitronectin was a gift from Deane Mosher, Univer-
sity of Wisconsin.
Alkylated and non-alkylated vitronectins were
each iodinated by incubating 200 Wg of protein
with 0.5 mCi Na125I (Du Pont-New England Nu-
clear) in the presence of lactoperoxidase (10 Wg/ml),
glucose oxidase (1 U/ml) and glucose (40 mM)
(Sigma). In the same manner, native vitronectin
was iodinated by incubating 50 Wg of protein with
0.125 mCi Na125I. The reactions were stopped after
5 min by adding excess tyrosine (10 mg/ml) together
with bromophenol blue. Free iodine was removed by
size exclusion chromatography on a G-25 Sephadex
¢ltration column (Pharmacia). Radiolabeled vitro-
nectin was stabilized by adding 0.1% phenylmethyl
sulfonyl £uoride treated BSA, then dialyzed against
PBS. Aliquots of the labeled proteins were £ash fro-
zen and stored at 380‡C until use. The integrity of
each protein was checked by autoradiography. Spe-
ci¢c activities were generally 1 WCi/Wg.
2.4. Binding and degradation of vitronectin
Binding and degradation of vitronectin were deter-
mined as previously described [1]. Brie£y, ¢broblast
monolayers were incubated with 125I-vitronectin or
125I-alkylated vitronectin at a ¢nal concentration of
620 ng/ml, in DMEM supplemented with either 0.2%
BSA (Sigma) or 0.4% Redu-SerII (Upstate Biotech-
nology, Lake Placid, NY) as indicated for the time
periods stipulated in each ¢gure legend. Medium
containing 125I-labeled vitronectin was removed,
and cells were rinsed 3 times with PBS to remove
unbound radioactivity. Cell layers were then solubi-
lized with 1 N NaOH, and bound radioactivity meas-
ured by Q-scintillation. Binding of 125I-labeled vitro-
nectin to cell layers could be competed with
unlabeled vitronectin, with speci¢c binding of vitro-
nectin to cell layers ranging between 70 and 80%.
Vitronectin degradation was determined by measur-
ing radioactivity in the conditioned medium that was
soluble in 10% trichloroacetic acid (TCA). Back-
ground degradation was determined in the absence
of cells by measuring the TCA soluble fraction of
125I-vitronectin in blank culture dishes which were
pretreated with DMEM containing 10% FBS. TCA
soluble background radioactivity was subtracted
from total TCA soluble radioactivity. Measurement
of TCA soluble radioactivity was done through
Q-scintillation. Values for both binding and degrada-
tion of 125I-labeled vitronectin were normalized by
converting to the percentage of total radioactivity
present in the incubation media.
2.5. Analysis of vitronectin multimers
To separate multimeric species of alkylated vitro-
nectin from monomeric forms, gel electrophoresis
was performed under both denaturing and non-de-
naturing conditions. For denaturing gels, proteins
were electrophoresed in a discontinuous bu¡er sys-
tem according to Laemmli [40], on either 8 or 10%
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SDS-polyacrylamide separating gels with a 3.3%
stacking gel. Bu¡ers utilized in SDS-PAGE analysis
consisted of: stacking gel bu¡er (0.125 M Tris; 0.1%
SDS; pH 6.8); separating gel bu¡er (75 M Tris;
0.2% SDS; pH 8.8); running bu¡er (0.025 M Tris;
0.192 M glycine; 0.1% SDS); (2U) sample bu¡er
(0.05 M Tris; 20% glycerin; 4% SDS) diluted 1/1
with sample. SDS-PAGE was routinely performed
at 15 mA through the stacking gel, followed by an
increase to 35 mA with cooling, through the separat-
ing gel. For non-denaturing gels, proteins were
also electrophoresed in a discontinuous bu¡er system
[40] on 6% native polyacrylamide separating gels
with a 3.3% stacking gel. Bu¡ers utilized in native
PAGE analysis consisted of: stacking gel bu¡er
(0.125 M Tris pH 6.8); separating gel bu¡er
(0.75 M Tris pH 8.8); running bu¡er (0.025 M
Tris; 0.192 M glycine); (5U) sample bu¡er
(0.125 M Tris; 50% glycerin) diluted 1/4 with sample.
Electrophoresis was performed at 40 V, for approx.
16^20 h. The results from gel electrophoresis of 125I-
labeled vitronectins were visualized by autoradiogra-
phy. Gels were dried under vacuum (Savant Speed-
Gel 200 Gel Dryer), then exposed to X-ray ¢lm
(Fuji).
Cell layer associated vitronectin was measured fol-
lowing incubation with 125I-vitronectin or alkylated
vitronectin for the times indicated in Fig. 4. Cell
layers were washed 3 times with PBS, then solubi-
lized in 75 Wl of (1U) SDS sample bu¡er. Solubilized
cell layers were expressed through a 25 gauge needle
to shear cellular DNA, then centrifuged at 10 000
rpm for 10 min. The supernatant was separated
from the pellet, and counted by Q-scintillation.
SDS-PAGE was performed, with equivalent levels
of radioactivity loaded for each time point. Proteins
were visualized by autoradiography.
For cross-linking experiments, aliquots of 125I-vi-
tronectin, 125I-alkylated vitronectin or 125I-native vi-
tronectin (approx. 10 Wg/ml) were incubated with or
without glutaraldehyde at a ¢nal working concentra-
tion of 0.05% in PBS, pH 7.4. Samples were incu-
bated at room temperature for 10 min, after which
an equivalent volume of (2U) SDS sample bu¡er
was added to each reaction vial. Samples were ana-
lyzed by 8% SDS-PAGE under both reducing and
non-reducing conditions, followed by autoradiogra-
phy.
3. Results
3.1. Characterization of multimeric forms of
vitronectin
Gel ¢ltration chromatography and native-PAGE
were done to verify that alkylated vitronectin was
in the form of multimers. Iodinated samples of either
conformationally altered vitronectin, which is known
to form high molecular weight, disul¢de stabilized
multimers, or alkylated vitronectin were chromato-
graphed on Sephacryl S-200. Each protein sample
appeared as a single peak in early column fractions
that were indicative of high molecular weight species
(data not shown). These ¢ndings were consistent
with results obtained from native-PAGE analysis of
each protein which, analyzed in the absence of reduc-
ing agent, revealed a high molecular weight species
for each form of vitronectin that migrated at the top
of the separating gel (Fig. 1A, arrow).
SDS-PAGE was performed under reducing and
non-reducing conditions in order to detect disul¢de
bond stabilized multimers. In the presence of reduc-
ing agent, both vitronectin (Fig. 1B, lane 1) and al-
kylated vitronectin (Fig. 1B, lane 2) migrated as the
65 and 75 kDa doublet characteristic of monomeric
vitronectin. The small migratory shift evident for al-
kylated vitronectin was presumably due to the addi-
tion of alkyl groups to cysteinyl residues. Under non-
reducing conditions, vitronectin remained at the in-
terface between stacking and separating gels (Fig.
1B, lane 3), indicating that vitronectin formed disul-
¢de stabilized multimers. In contrast, alkylated vitro-
nectin (Fig. 1B, lane 4) migrated at 65 and 75 kDa in
the absence of reducing agent, con¢rming that these
multimers were not stabilized by covalent bonds.
To substantiate further that alkylated vitronectin
was aggregating into multimers, cross-linking experi-
ments were performed. Samples of either multimeric
vitronectin, alkylated vitronectin or native vitronec-
tin were diluted into PBS at a ¢nal concentration of
approx. 10 Wg/ml, and cross-linked with 0.05% glu-
taraldehyde. This was followed by SDS-PAGE anal-
ysis in the presence of reducing agent. Fig. 2 shows
that following cross-linking, both reduced alkylated
vitronectin and reduced vitronectin migrated as high
molecular weight multimers (lanes 1 and 3), while in
the absence of cross-linking agent both proteins mi-
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grated as monomers (lanes 2 and 4). In contrast to
this, native vitronectin migrated as a monomer in
both the presence (lane 5) and absence (lane 6) of
cross-linking agent. The appearance of a single na-
tive vitronectin band (approx. 75 kDa) (lane 5) in the
presence of glutaraldehyde is most likely the result of
cross-linking the disul¢de bonded 65 kDa and 10
kDa pieces of vitronectin.
Taken together, these ¢ndings suggest that alky-
Fig. 2. Cross-linking of vitronectin multimers. 125I-Labeled sam-
ples of vitronectin (lanes 1 and 2), alkylated vitronectin (lanes 3
and 4), or native vitronectin (lanes 5 and 6) were subjected to
cross-linking with 0.05% glutaraldehyde in TBS for 10 min
(lanes 1, 3 and 5) followed by SDS-PAGE under reducing con-
ditions, then visualized by autoradiography. Lanes 2, 4 and 6
represent control conditions in which protein samples were di-
luted into an equivalent amount of TBS in the absence of
cross-linking agent. Molecular mass markers (kDa) are indi-
cated on the right. The arrow indicates the interface between
stacking and separating gels.
6
Fig. 1. (A) Native-PAGE analysis of vitronectin multimers.
125I-Labeled samples of vitronectin (lane 1) and alkylated vitro-
nectin (lane 2) were subjected to 6.0% non-denaturing PAGE,
followed by autoradiography. The arrow signi¢es the interface
between stacking and separating gels. (B) SDS-PAGE analysis
of vitronectin multimers. 125I-Labeled samples of vitronectin
(lanes 1 and 3) and alkylated vitronectin (lanes 2 and 4) were
separated by gel electrophoresis on a 10% SDS-polyacrylamide
gel, under both reducing (lanes 1 and 2) and non-reducing
(lanes 3 and 4) conditions. Proteins were visualized by autora-
diography. Molecular mass markers (kDa) are indicated.
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lated vitronectin forms a species of multimer that
does not require either intra- or intermolecular disul-
¢de stabilization, but appears to be dependent upon
non-covalent interactions which are disrupted in the
presence of a denaturant such as SDS. In contrast,
multimers which arise from the puri¢cation of urea
treated vitronectin remain stable in the presence of
SDS, yet are sensitive to reducing agents.
Fig. 3. Binding and degradation of vitronectin multimers by ¢-
broblast cell layers. Con£uent ¢broblast monolayers were
treated for 3 days with 50 Wg/ml ascorbic acid in DMEM sup-
plemented with 10% FBS. Cell layers were washed twice with
PBS, then once with plain DMEM after which 125I-labeled vi-
tronectin (A) or alkylated vitronectin (B) was added at a con-
centration of 620 ng/ml in DMEM containing 0.4% Redu-SerII.
At 4, 9, 19 and 24 h cell layers were processed to evaluate
binding and degradation of vitronectin multimers. The bound
fraction was determined to be the radioactivity which remained
associated with the cell layer following three washes with PBS.
Degradation of 125I-labeled vitronectin or alkylated vitronectin
was determined by measuring the TCA soluble radioactivity
present in the medium at each time point. The data represent
the average of triplicates þ S.E.
Fig. 4. SDS-PAGE analysis of cell layer associated vitronectin.
Con£uent ¢broblast monolayers were ascorbate treated for 3
days in DMEM supplemented with 10% FBS. Cell layers were
washed with PBS and DMEM, then incubated with either 125I-
labeled alkylated vitronectin (A) or 125I-labeled vitronectin (B)
in DMEM containing 0.2% BSA for the designated time period.
At each of the indicated time points, cell layers were washed
with PBS then solubilized in (1U) SDS sample bu¡er and ana-
lyzed by SDS-PAGE followed by autoradiography. 125I-Labeled
vitronectin or alkylated vitronectin that had not been incubated
with cell layers was also electrophoresed to account for the pro-
tein structures present in the starting material (S.M.) In panel
B the single arrow indicates the interface between stacking and
separating gels; the double arrows indicate the high molecular
weight aggregates at the top of the stacking gel.
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3.2. Degradation of vitronectin multimers by A1F
¢broblasts
In earlier studies, we have shown that endocytosis
and degradation of vitronectin by ¢broblast mono-
layers occur following changes in the conformation
of the molecule, and may require conversion to a
multimeric form [1,2]. We have also shown that bind-
ing of vitronectin multimers to sulfated proteogly-
cans precedes the degradation of vitronectin [1,27].
Since the multimeric form of vitronectin utilized in
those studies was puri¢ed under denaturing condi-
tions and therefore stabilized by disul¢de bonds, we
were interested in determining whether alkylated
multimeric vitronectin would also be recognized for
endocytosis and degradation by ¢broblast cell layers.
Fig. 3 shows that similar to vitronectin (Fig. 3A),
alkylated vitronectin (Fig. 3B) was also degraded
by A1F ¢broblasts, suggesting that alkylated multi-
mers were also present in a conformation which
could be recognized for endocytosis.
3.3. Characterization of cell associated vitronectins
Since vitronectin is a substrate for cellular trans-
glutaminases [41], we asked whether either species of
vitronectin multimer became covalently modi¢ed by
the presence of cell associated transglutaminases pos-
sibly present in ¢broblast monolayers. Cell layers
were incubated with either 125I-vitronectin or 125I-al-
kylated vitronectin for up to 24 h. At 6, 9, 12 and
24 h time points cell layers were solubilized in SDS
sample bu¡er, then analyzed by SDS-PAGE. Fig. 4A
shows that over the course of 24 h, cell layer asso-
ciated alkylated vitronectin did not form any higher
order aggregate structures. Alkylated vitronectin, ei-
ther in the presence or absence of reducing agent,
migrated as a monomer. This observation demon-
strates that once bound to the cell layer, alkylated
vitronectin multimers do not convert to an SDS sta-
ble conformation, indicating that these multimers are
not becoming covalently cross-linked. In contrast,
non-alkylated vitronectin exhibited a time dependent
conversion to a higher order aggregated species. This
species accumulated as a high molecular weight form
which appeared at the top of the stacking gel in the
absence of reducing agent (Fig. 4B, double arrow).
There appeared to be a concomitant loss of material
from the lower molecular weight band (single arrow),
suggesting that the material at the top of the stack
resulted from a conversion of the lower molecular
weight species into a higher order aggregate. In the
presence of reducing agent, both low and high mo-
lecular weight multimers migrated as the 75/65 dou-
blet suggesting that the higher order multimers did
not result from any cell associated transglutaminases,
Fig. 5. E¡ects of chlorate on binding and degradation of multi-
mers. Con£uent ascorbate treated ¢broblast monolayers were
incubated with DMEM supplemented with 20% dialyzed FBS
and 0, 15, 30, 50 or 100 mM sodium chlorate for 3 days. Fol-
lowing chlorate pretreatment, cell layers were incubated for 20 h
with DMEM containing either 125I-labeled vitronectin (Vn) or
alkylated vitronectin (alkylated Vn) and 0.2% BSA. Treatment
with chlorate was continued throughout the incubation with ra-
diolabeled protein. Bound 125I-vitronectin or alkylated vitronec-
tin was determined to be the radioactivity which remained asso-
ciated with the cell layer following washes with PBS (A). In
panel B, degradation of 125I-vitronectin or 125I-alkylated vitro-
nectin was monitored by measuring the TCA soluble radioactiv-
ity present in the medium following the 20 h incubation period.
The data represent the average of triplicates þ S.E.
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but occurred through intermolecular cross-links re-
sulting from disul¢de rearrangement.
3.4. Binding and degradation of alkylated vitronectin
multimers are dependent upon sulfated
proteoglycans
As previously mentioned, binding of vitronectin to
heparan sulfate proteoglycans present in the extra-
cellular matrix of ¢broblast monolayers precedes its
endocytosis by the KvL5-integrin [1,27,42]. To deter-
mine whether alkylated vitronectin also bound to
sulfated proteoglycans in the cell layer prior to en-
docytosis, con£uent ¢broblast monolayers were
treated with sodium chlorate to prevent sulfation of
proteoglycans. Sodium chlorate is a competitive in-
hibitor of ATP sulfurylase. It interferes with the for-
mation of the biological sulfate donor 3P-phosphoa-
denosine-5P-phosphosulfate (PAPS) [43,44] and
subsequently results in the production of sulfate de-
¢cient proteoglycans [37,45,46]. We have previously
demonstrated that the addition of sodium chlorate to
¢broblast monolayers results in decreased levels of
vitronectin binding and degradation coincident with
a decrease in sulfate levels present in the matrix [27].
We have also shown that removal of chlorate from
these monolayers results in the recovery of vitronec-
tin binding and degradation concomitant with a res-
Fig. 6. E¡ects of RGD peptides on degradation of vitronectin
multimers. Con£uent ¢broblast cell layers that had been ascor-
bate treated for 3 days were washed twice with PBS and once
with DMEM. Cell layers were incubated for 15 h in DMEM
supplemented with 0.2% BSA, and either 125I-labeled vitronectin
(A) or 125I-alkylated vitronectin (B) in the presence of RGDS
or RGES peptides, at the concentrations indicated. At the end
of 15 h, degradation of vitronectin was assessed by measuring
the amount of TCA soluble radioactivity present in the me-
dium. The data represent the average þ S.E. where n = 2.
Fig. 7. E¡ects of KvL5 antibody or heparin on degradation of
vitronectin multimers. For the e¡ects of the KvL5 antibody, con-
£uent ascorbate treated ¢broblasts were washed, then incubated
with DMEM containing 0.4% Redu-SerII, and 125I-vitronectin
(Vn) or 125I-alkylated vitronectin (alkylated Vn), with or with-
out 20 Wg/ml of the monoclonal antibody P1F6. Following a
17 h incubation period, the medium was removed and the
amount of TCA soluble radioactivity determined in order to
measure the level of vitronectin degradation. The data represent
the average þ S.E. where n = 2. For the e¡ects of exogenous hep-
arin, 125I-vitronectin (Vn) or alkylated vitronectin (alkylated
Vn) was preincubated for 1 h with 0.25 mg/ml heparin in
DMEM containing 0.2% BSA prior to its addition to ascorbate
treated ¢broblast monolayers. Following a 17 h incubation peri-
od with heparin/125I-vitronectin, the medium was removed from
the cell layers, and degradation of vitronectin assessed by meas-
uring the TCA soluble fraction of radioactivity. The data repre-
sent the average of triplicates þ S.E.
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toration in proteoglycan sulfation [27]. These earlier
experiments therefore suggest a direct correlation be-
tween proteoglycan sulfation and vitronectin metab-
olism. Similar to results seen with vitronectin, bind-
ing and degradation of alkylated vitronectin
multimers were also inhibited in a dose dependent
manner, by increasing concentrations of sodium
chlorate (Fig. 5A,B). These results suggest that like
vitronectin, alkylated vitronectin multimers bind to
¢broblast monolayers via an interaction with sul-
fated proteoglycans. These results further suggest
that endocytosis and degradation of alkylated vitro-
nectin are dependent upon this interaction.
3.5. Degradation of vitronectin multimers is regulated
by integrin dependent and heparin sensitive
mechanisms
In previous studies, we have shown that degrada-
tion of vitronectin multimers occurs via receptor
mediated endocytosis that is dependent upon the
KvL5-integrin [28]. To determine whether degradation
of alkylated vitronectin also involved integrin de-
pendent mechanisms, arginine-glycine-aspartic acid
(RGD) peptides were added in the presence of 125I-
labeled vitronectins to compete vitronectin-integrin
interactions. In agreement with previous ¢ndings
[28], degradation of vitronectin multimers was inhib-
itable with RGD peptides (Fig. 6A). Similarly, deg-
radation of alkylated vitronectin multimers was also
reduced in the presence of increasing concentrations
of RGD peptides (Fig. 6B) suggesting that alkylated
vitronectin multimers were endocytosed in an integ-
rin dependent manner. Inhibition was speci¢c for
RGD since RGE peptides had no e¡ect on degrada-
tion. Maximal inhibition of approx. 50% degradation
occurred at 1.0 mM for both forms of vitronectin
multimers.
Antibodies against KvL5 were also tested for their
ability to block degradation of alkylated vitronectin.
Fibroblast monolayers were incubated with 125I-la-
beled vitronectins in the presence of the anti KvL5
antibody P1F6. As can be seen in Fig. 7, P1F6 at
20 Wg/ml was able to inhibit degradation of alkylated
vitronectin by approx. 52%. This was comparable to
the level of inhibition achieved for non-alkylated vi-
tronectin. It therefore, appears that both species of
vitronectin multimers are endocytosed and degraded
by an KvL5 dependent mechanism.
Binding and degradation of vitronectin have also
been shown to be sensitive to the addition of exoge-
nous heparin [1,27,42], suggesting that an interaction
between the cell layer and the heparin binding region
Fig. 8. E¡ects of wortmannin and chloroquine, on the degrada-
tion of vitronectin multimers. Con£uent ascorbate treated ¢bro-
blast monolayers were washed, then pretreated for 15 min with
DMEM containing 0.2% BSA and either 10 WM wortmannin
(A) or 100 WM chloroquine (B) prior to the addition of 125I-vi-
tronectin (Vn) or alkylated vitronectin (alkylated Vn) at 620
ng/ml. In panel A, control wells received an equivalent volume
of DMSO as the control vehicle for wortmannin. Following an
incubation time totaling 7 h, the medium was removed and as-
sessed for degradation of vitronectin by measuring the TCA
soluble radioactivity. In panel B, cell layers treated with chloro-
quine were incubated with 125I-vitronectin or 125I-alkylated vi-
tronectin for 17 h, after which the level of vitronectin degrada-
tion was assessed by measuring the TCA soluble radioactivity.
The data represent the average of triplicates þ S.E.
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of the vitronectin molecule is necessary for its endo-
cytosis. In order to determine whether the heparin
binding region was also required for the degradation
of alkylated vitronectin multimers, ¢broblast cell
layers were incubated with 125I-labeled vitronectins
in the presence of exogenous heparin. As can be
seen in Fig. 7, the addition of 250 Wg/ml of heparin
led to a 65% decrease in degradation of both species
of vitronectin multimers. The concentration of hep-
arin chosen in this experiment was expected to inhib-
it vitronectin degradation by 50^75% based on ear-
lier studies [27]. These results demonstrate that
mechanisms involved in the degradation of alkylated
vitronectin multimers, like non-alkylated vitronectin
multimers, are sensitive to heparin and likely depend-
ent upon interaction(s) between the heparin binding
region of the molecule and proteoglycans present in
the cell layer.
3.6. Vitronectin multimers are endocytosed and
targeted to lysosomes for degradation
Previous studies have shown that degradation of
vitronectin is inhibited with chloroquine and wort-
mannin [1,26]. Chloroquine inhibits lysosomal en-
zymes [47], while wortmannin, depending on the
dose, inhibits PI-3 kinase and myosin light chain
kinase [48] and prevents the tra⁄cking of endosomes
containing vitronectin to lysosomes [26]. In order to
determine whether alkylated vitronectin multimers
were endocytosed in a manner similar to that ob-
served for non-alkylated vitronectin multimers, ex-
periments were performed to de¢ne the endocytic
pathway involved in its degradation. Cell layers
that were treated with either wortmannin or chloro-
quine demonstrated approx. a 65% reduction in deg-
radation of both forms of vitronectin (Fig. 8). Inhib-
ition of vitronectin degradation by wortmannin was
seen at doses as low as 500 nM; however, increasing
doses resulted in higher levels of inhibition, suggest-
ing that degradation of both species of vitronectin
multimers occurred via a myosin-light chain kinase
dependent pathway [48]. It therefore appears that
regardless of its inability to form disul¢de bond sta-
bilized multimers, alkylated vitronectin forms multi-
mers that are still recognized for endocytosis by ¢-
broblast cell layers and subsequently directed to
lysosomes for degradation. Taken together, the re-
sults from this study indicate that both species of
multimeric vitronectin are degraded through a com-
mon endocytic pathway that depends upon the inter-
action of vitronectin with both sulfated proteogly-
cans and the KvL5-integrin.
4. Discussion
In vivo, vitronectin has been shown to exist in at
least two distinct states, as a monomer and as a
multimer [5,6]. Monomeric vitronectin circulates in
the blood plasma while multimeric forms of vitronec-
tin are stored in platelets [6] and released in response
to platelet activation [7]. Homo-multimerization of
vitronectin can also be triggered by PAI-1 [35] and
heparin [36], suggesting that the binding of physio-
logically relevant ligands can promote conformation-
al changes which result in the multimerization of
vitronectin. The conversion of monomeric vitronec-
tin to multimeric vitronectin appears to be function-
ally signi¢cant, since multimerization of vitronectin
has been associated with exposure of binding sites
for PAI-1 and integrin [36,49] and is associated
with increased rates of clearance [1,23,24]. Studies
have shown that in vivo, vitronectin multimers can
exist as either covalently or non-covalently stabilized
structures [5^7]. However, the biological signi¢cance
of this structural dichotomy is still under investiga-
tion.
Characteristics of multimerized vitronectin appear
to be dependent upon the type of method used to
purify the protein. Several studies substantiate the
formation of vitronectin multimers stabilized
through either covalent (disul¢de) [8,10,19,20,35,36]
or non-covalent [10,19,20,35,36] interactions, follow-
ing puri¢cation or denaturation of the protein. Vi-
tronectin puri¢ed under urea denaturing conditions
[18] results in the formation of disul¢de stabilized
multimers [10,20]. Interestingly, the multimeric form
of vitronectin that is puri¢ed from platelet K granules
and platelet releasate is also disul¢de stabilized; how-
ever, these two multimeric forms of vitronectin di¡er
in both size and conformation [6]. Similarly, our
cross-linking experiments shown in Fig. 2 indicate
that alkylated vitronectin multimers contain a high
molecular weight species, not seen in the non-alky-
lated multimers. Taken together, these observations
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suggest that vitronectin has the capacity to undergo a
variety of diverse structural changes, the exact signif-
icance of which remains to be determined.
We have previously demonstrated that conforma-
tional di¡erences in vitronectin’s structure trigger its
endocytosis and lysosomal degradation by ¢broblasts
in culture [1,2]. Although these studies, as well as the
current one, used 125I-labeled vitronectin, similar re-
sults were also obtained in experiments which uti-
lized unlabeled vitronectin [1,26] demonstrating that
the iodination process itself does not a¡ect the me-
tabolism of vitronectin. These studies have also
shown that endocytosis of multimeric vitronectin
was dependent upon the interaction of vitronectin
with sulfated proteoglycans [27] and the KvL5-integ-
rin [28].
In order to compare the mechanisms of endocyto-
sis and degradation of alkylated vitronectin multi-
mers with those previously observed for non-alky-
lated multimeric vitronectin, a series of experiments
that had been used to de¢ne the endocytic pathway
for non-alkylated vitronectin were performed. So-
dium chlorate treatment of ¢broblast monolayers,
which has been utilized in several studies to de¢ne
mechanisms that are dependent upon sulfated pro-
teoglycans [50^54], resulted in a dose dependent de-
crease for both binding and degradation of alkylated
vitronectin multimers. Degradation of alkylated vi-
tronectin was also inhibited with increasing concen-
trations of exogenous heparin. Taken together, the
inhibitory e¡ects of sodium chlorate and heparin on
the degradation of alkylated vitronectin suggest that,
as has been previously shown for non-alkylated vi-
tronectin [27], endocytosis of alkylated vitronectin is
modulated through interactions involving the hepa-
rin binding domain of vitronectin with heparan sul-
fate proteoglycans.
Degradation of alkylated vitronectin was also in-
hibited with RGD peptides and the monoclonal anti-
body P1F6 suggesting that like the disul¢de stabi-
lized multimers, endocytosis of alkylated vitronectin
multimers was also modulated by an RGD depend-
ent interaction with the KvL5-integrin. Inhibition of
vitronectin degradation by RGD was only partial,
reaching a maximum at 50%. We have routinely en-
countered an inability to suppress completely the
degradation of vitronectin with RGD peptides [28].
This inability to totally block KvL5 function with
RGD peptides has also been described by Vogel et
al. [55] and by Cheresh et al. [56] who suggest the
possibility that the KvL5-integrin has alternative li-
gand binding a⁄nities.
While our current study shows a 50% inhibition of
vitronectin degradation with 20 Wg/ml P1F6, we have
been able to demonstrate up to 80% inhibition when
P1F6 was added at a concentration of 50 Wg/ml [28].
It therefore remains possible that a certain level of
vitronectin degradation (approx. 20%) may be medi-
ated by alternative endocytic pathways. Thrombo-
spondin, a platelet protein also found associated
with the ECM, has been shown to be endocytosed
by the low density lipoprotein receptor-related pro-
tein (LRP) and targeted to lysosomes for degrada-
tion [57,58]. Previous studies have shown that unlike
thrombospondin, vitronectin degradation by this
pathway appeared minimal [58]. Nevertheless, the
possibility remains that a small proportion of vitro-
nectin may be internalized by this or other mecha-
nisms.
Taken together, these results suggest that alkylated
vitronectin multimers are organized in a manner
which enables them to interact with both the KvL5-
integrin as well as sulfated proteoglycans, molecules
which have been shown to modulate the endocytosis
of disul¢de stabilized multimers. Vitronectin contains
14 cysteine residues that may contribute signi¢cantly
to its tertiary structure. Reduction and alkylation of
vitronectin would therefore be expected to disrupt
conformationally dependent ligand binding domains.
Sei¡ert et al. have recently shown that the high af-
¢nity binding site for PAI-1, located in the somato-
medin B domain, is lost following treatment of vi-
tronectin with reducing agents, suggesting that this
binding site is dependent on disul¢de stabilized ter-
tiary structure for its function [59]. The ‘RGD-con-
taining’ connecting region and the heparin binding
domain were una¡ected, however, suggesting that
these domains are not subject to disul¢de-dependent
conformational constraint. The fact that alkylated
vitronectin multimers are endocytosed and degraded
implies that the receptor interactions involved in the
binding and degradation of vitronectin are depend-
ent upon the linear sequences of amino acids in each
ligand binding domain. This is consistent with a
model in which vitronectin’s RGD and heparin bind-
ing consensus sequences are the primary receptor
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binding sites responsible for vitronectin endocytosis.
Interestingly, it has recently been suggested that the
cell adhesion (RGD) domain is cryptic in native
monomeric vitronectin [49], and that binding of na-
tive vitronectin to sulfated glycosaminoglycans indu-
ces a conformational change in the molecule which
results in the exposure of N-terminal ligand binding
domains, including the cryptic RGD site [36]. Taken
together, these studies suggest that binding of native
vitronectin to sulfated proteoglycans in the extracel-
lular matrix should invoke conformational change
and expose the RGD site which appears to be neces-
sary for vitronectin endocytosis [1,2,27,28,36,49].
Native monomeric vitronectin is not, however, endo-
cytosed. A model which reconciles all these observa-
tions would be one in which endocytosis and degra-
dation of vitronectin is triggered by its multivalency
rather than by changes in its tertiary structure.
Non-alkylated disul¢de bonded multimers, in con-
trast to alkylated multimers, formed higher order cell
layer associated aggregates that were also disul¢de
stabilized. The mechanism which resulted in the for-
mation of these higher order multimers is not known,
but might arise from intermolecular disul¢de rear-
rangements or disul¢de dependent interactions with
other matrix constituents. Alkylation of vitronectin
may have prevented these multimers from under-
going this secondary stabilizing event. Sei¡ert et al.
have suggested that the PAI-1 dependent homo-mul-
timerization of plasma vitronectin initially occurs
through non-covalent interactions between vitronec-
tin subunits, which later become disul¢de stabilized
in a time dependent and possibly heparin dependent
manner [35,36]. The relationship of the chemically
induced multimers described in the present study to
those which are triggered by PAI-1 represent an in-
teresting avenue for future investigation.
Multimeric vitronectin, and PAI-1 which induces
multimerization of plasma vitronectin [35], are both
found in platelet K granules [6], suggesting that these
molecules are involved in procoagulant events fol-
lowing platelet activation. In addition to this, the
production of PAI-1 by cells has also been shown
to increase in areas that have sustained tissue dam-
age [60]. A localized ampli¢cation in the level of
PAI-1 following trauma to the vasculature and sur-
rounding tissues may serve to recruit and multimer-
ize plasma vitronectin, augmenting the level of multi-
meric vitronectin present at the site of injury. PAI-1
induced multimers of vitronectin are initially stabi-
lized by non-covalent interactions [35]; it would
therefore appear that these interactions may be cru-
cial in rapidly establishing a high level of multivalent
vitronectin that could initially modulate coagulative
events. Since vitronectin represents the primary bind-
ing site for PAI-1 in the matrix [33,61], clearance of
multimeric vitronectin following the initial incidence
of hemostasis would facilitate a shift from a procoa-
gulant environment to one that favors ¢brinolysis
and tissue repair.
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